Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that XBiotech Inc. made materially false and/or misleading statements and/or failed to disclose that: XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint. Specifically, the Company noted that "substantial irregularities that make unequivocal interpretation of the findings difficult." Following this news, XBiotech's stock price sharply fell during intraday trading on the same day.
In order to be eligible to join the XBIT class action lawsuit, you must have incurred a loss on shares of XBiotech Inc. purchased during the class period listed above.
TOP
